medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

salud publica mex 2016; 58 (2)

Prostate cancer mortality according to marginalization status in Mexican states from 1980 to 2013

Torres-Sánchez LE, Espinoza-Giacinto R, Rojas-Martínez R, Escamilla-Nuñez C, Vázquez-Salas RA, Campuzano JC, Lazcano-Ponce E

Language: English
References: 31
Page: 179-186
PDF size: 244.21 Kb.


ABSTRACT

Objective. To assess prostate cancer (PC) mortality in Mexico from 1980 to 2013, according to the state marginalization level. Materials and methods. Using age-adjusted rates in men ≥ 40 years old, we estimated trends and agecohort- period effects of PC mortality from 1980-2013 according to state marginalization status by using a joinpoint regression model and a Poisson regression model proposed by Holford. Results. The PC mortality risk has increased nationwide at a constant rate (2% annually) during the past 13 years. The highest annual increase was observed among states with very high (4.4%) and high (7.7%) marginalization rates. In contrast, states with very low levels of marginalization showed a significant reduction of 1.5% per year. The main changes were observed in the 1945-1950 birth year cohorts. Conclusions. Differences in PC mortality across regions of Mexico may reflect differences in the timing of the diagnosis and treatment of PC.


REFERENCES

  1. IARC/WHO. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence Worldwide in 2012 [accessed May 20, 2014]. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

  2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.

  3. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341:c4543.

  4. Lee YJ, Park JE, Jeon BR, Lee SM, Kim SY, Lee YK. Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review. Ann Lab Med 2013;33:233-241.

  5. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009;53:171-184.

  6. Gomez-Guerra LS, Martinez-Fierro ML, Alcantara-Aragon V, Ortiz-Lopez R, Martinez-Villarreal RT, Morales-Rodriguez IB, et al. Population-based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases. BMC Cancer 2009;24:91.

  7. Torres-Sánchez L, Vázquez-Salas RA, López-Carrillo L, Manzanilla-García HA, Cruz-Ortíz CH, Mendoza-Peña F, et al. Antecedentes de gonorrea y riesgo de cáncer de próstata en hombres mexicanos. Resultados preliminares. Rev Mex Urol 2013;73 (supp 1):105-106.

  8. Tovar-Guzmán V, Hernandez-Giron C, Lopez-Rios O, Lazcano-Ponce EC. Prostate cancer mortality trends in Mexico, 1980-1995. Prostate 1999;39:23-27.

  9. Malvezzi M, Bosetti C, Chatenoud L, Rodríguez T, Levi F, Negri E, et al. Trends in cancer mortality in Mexico, 1970–1999. Ann Oncol 2004;15:1712-1718.

  10. Torres-Sánchez LE, Rojas-Martínez R, Escamilla-Núñez C, de la Vara- Salazar E, Lazcano-Ponce E. Tendencias en la mortalidad por cáncer en México de 1980 a 2011. Salud Publica Mex 2014;56:473-491.

  11. INEGI. Regiones Socioeconómicas de México 2000. Available at: http:// sc.inegi.gob.mx/niveles/datosnbi/reg_soc_mexico.pdf

  12. Bustos A. Niveles de marginación: una estrategia multivariada de clasificación. Realidad, datos y espacio revista internacional de estadística y geografía 2011;2:169-186.

  13. Dirección General de Información en Salud (DGIS). Base de datos de defunciones 1979-2011 [on line]: Sistema Nacional de Información en Salud (SINAIS). México: Secretaría de Salud [accessed June, 2013]. Available at: http://www.sinais.salud.gob.mx

  14. World Health Organization. International Classification of Disease: 9th revision. Geneva: World Health Organization, 1977.

  15. World Health Organization. International Classification of Disease and related Health Problems: 10th revision. Geneva: World Health Organization, 1992.

  16. Consejo Nacional de Población. Proyecciones de la población de México, 1990-2010, 2010-2050. México. CONAPO [accessed May 16, 2013]. Available at: http://www.conapo.gob.mx/es/CONAPO/Proyecciones.

  17. Gordis L. Epidemiología, 3rd ed, Génova: Elsevier España, 2005.

  18. Consejo Nacional de Población (Conapo). Dirección General de Planeación en Población y Desarrollo ⁄ Índices de Marginación [accessed Abril 15, 2015]. Available at: http://www.conapo.gob.mx/es/CONAPO/ Indices_de_Marginacion

  19. Kim H, Fay M, Feuer E, Midthune D. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351.

  20. Holford TR. The Estimation of Age, Period and Cohort Effects for Vital Rates. Biometrics 1983;39:311-324.

  21. Surveillance Research. Joinpoint Regression Program. Cancer control and population sciences; 2013; Version 4.0.4. [accessed May 16, 2013]. Available at: http://surveillance.cancer.gov/joinpoint/]

  22. da Silva JF, Mattos IE, Aydos RD. Tendencies of mortality by prostate cancer in the states of the Central-West Region of Brazil, 1980-2011. Rev Bras Epidemiol 2014;17:395-406.

  23. Conceição MB, Boing AF, Peres KG. Time trends in prostate cancer mortality according to major geographic regions of Brazil: an analysis of three decades. Cad Saude Publica 2014;30:559-566.

  24. Ilic M, Ilic I. Prostate cancer mortality in Serbia, 1991-2010: a joinpoint regression analysis. J Public Health (Oxf) 2015:pii: fdv064.

  25. Politis M, Higuera G, Chang LR, Gomez B, Bares J, Motta J. Trend Analysis of Cancer Mortality and Incidence in Panama, Using Joinpoint Regression Analysis. Medicine (Baltimore) 2015;94:e970.

  26. Restrepo JA, Bravo LE, García-Perdomo HA, García LS, Collazos P, Carbonell J. Incidencia, mortalidad y supervivencia al cáncer de próstata en Cali, Colombia, 1962-2011. Salud Publica Mex 2014;56:440-447.

  27. Du XL, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006;106:1276-1285.

  28. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.

  29. Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JE. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003;1:242-247.

  30. Secretaría de Salud. Rendición de Cuentas en Salud 2011. SSa México 2012. ISBN 978-607-460-292-0 [accessed May 2014]. Available at: http:// www.dged.salud.gob.mx/contenidos/dedss/descargas/rcs/RCS_2011.pdf

  31. Muñoz N, Knaul F, Lazcano E. 50 años del Registro Poblacional de Cáncer de Cali, Colombia. Salud Publica Mex 2014;56:421-422.




2020     |     www.medigraphic.com